Corrigendum: Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α

Affiliations

• ¹ Division of Gastroenterology, Icahn School of Medicine Mount Sinai, New York, NY, United States.
• ² St Vincent's Hospital and The University of Melbourne, Melbourne, VIC, Australia.
• ³ Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
• ⁴ IRCCS Azienda Ospedaliero-Universitaria di Bologna Italy, Bologna, Italy.
• ⁵ DIMEC University of Bologna-Italy, Bologna, Italy.
• ⁶ F. Widjaja Inflammatory Bowel Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
• ⁷ Research and Development, Prometheus Laboratories, San Diego, CA, United States.